Replimune REPL 深 沪
等待开盘 04-02 09:30:00 美东时间
7.61
-0.040
-0.52%
华盛通- 最 高7.9274
- 今 开7.72
- 成交量 109.56万股
- 最 低 7.59
- 昨 收 7.65
- 总市值 6.28亿
- 52周最高 13.24
- 市盈率 静 --
- 换手率 1.33%
- 52周最低 2.68
- 委 比 73.70%
- 总股本 8257.26万
- 历史最高 54.79
- 量 比 0.69
- 振 幅 4.41%
- 历史最低 2.68
- 每 手 1
- 风险率 2.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Phreesia, Service Properties Trust, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures rise on Tuesday with Dow futures up 400 points. Phreesia shares fall 26.5% in pre-market after mixed Q4 results and lower sales guidance. Other stocks also decline.
03-31 20:01
新浪财经ESG：Replimune Group Inc. MSCI（明晟）ESG评级调降至B
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:29
Replimune management to present at Leerink Partners Global Healthcare Conference and host investor meetings at Jefferies Biotech on the Beach Summit
Replimune management to present at Leerink Partners Global Healthcare Conference and host investor meetings at Jefferies Biotech on the Beach Summit Replimune Group Inc. will present and host investor meetings at two upcoming conferences: the Leerink Partners 2026 Global Healthcare Conference on Mar
03-02 21:01
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. announced that its management will participate in two conferences: the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026, with a fireside chat at 2:20 pm EDT, and the Jefferies 2026 Biotech on the Beach Summit on March 10, 2026, for 1x1 meetings. A live webcast of the fireside chat will be available on Replimune’s website at [www.replimune.com](https://www.replimune.com), with a replay available for 30 days...
03-02 13:00
美股大行评级 | 谷歌绩后获14家大行上调目标价；Arm、高通、波士顿科学、艾可菲、Snap、优步遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Wave Life Sciences Ltd."超配"评级，目标价从34美元升至41美元；Piper Sandler：维持Replimune Group"超配"评级，目标价从13美元升至14美元
02-06 16:52
美股大行评级 | 泰瑞达、Lumentum、哈贝尔、Enphase能源、西部数据获多家机构上调目标价；PayPal 、恩智浦、墨式烧烤遭多家机构下调目标价
今日重点评级关注：韦德布什：维持Replimune Group"跑赢大市"评级，目标价从18美元升至19美元；巴克莱：维持CytomX Therapeutics"超配"评级，目标价从8美元升至10美元
02-05 11:28
Wedbush Maintains Outperform on Replimune Group, Raises Price Target to $19
Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $18 to $19.
02-04 22:35
财报速睇 | Replimune 2026财年三季报营收0.00亿美元，同比增长0.0%；归母净利润亏损0.71亿美元，同比亏损扩大6.9%
Replimune 2026财年三季报营收0.00亿美元，同比增长0.0%；归母净利润亏损0.71亿美元，同比亏损扩大6.9%
02-03 23:20
财报速睇 | Replimune 2026财年三季报营收0.00亿美元，同比增长0.0%；归母净利润亏损0.71亿美元，同比亏损扩大6.9%
Replimune 2026财年三季报营收0.00亿美元，同比增长0.0%；归母净利润亏损0.71亿美元，同比亏损扩大6.9%
02-03 22:47
Replimune Group Q3 Earnings Summary & Key Takeaways
Replimune Group (NASDAQ:REPL) announced its Q3 earnings on Tuesday, February 3,...
02-03 21:38
